Myovant Sciences Ltd - ESG Rating & Company Profile powered by AI
The analysis of Myovant Sciences Ltd employs information from across the internet and also from public disclosures by Myovant Sciences Ltd. The webpage displays a zero-cost Environmental, Social and Governance assessment for Myovant Sciences Ltd. The page contains a Q&A section for Myovant Sciences Ltd.
Myovant Sciences Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.6; made up of an environmental score of 3.2, social score of 8.0 and governance score of 8.0.
6.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 446 | STADA Arzneimittel AG | 6.7 | High |
| 446 | Valeo Pharma Inc | 6.7 | High |
| 483 | Myovant Sciences Ltd | 6.6 | High |
| 483 | Bal Pharma Ltd | 6.6 | High |
| 483 | Adicet Bio Inc | 6.6 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Myovant Sciences Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Myovant Sciences Ltd report the average age of the workforce?
Sign up for free to unlockDoes Myovant Sciences Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Myovant Sciences Ltd offer flexible work?
Sign up for free to unlockDoes Myovant Sciences Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Myovant Sciences Ltd conduct supply chain audits?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Myovant Sciences Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose water use targets?
Sign up for free to unlockDoes Myovant Sciences Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Myovant Sciences Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Myovant Sciences Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Myovant Sciences Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Myovant Sciences Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Myovant Sciences Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Myovant Sciences Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose its waste policy?
Sign up for free to unlockDoes Myovant Sciences Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose energy use targets?
Sign up for free to unlockDoes Myovant Sciences Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Myovant Sciences Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Myovant Sciences Ltd
These potential risks are based on the size, segment and geographies of the company.
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.